Lamivudine

• Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 … Recruiting
  2023-508634-34-00 Phase II 1 country Inserm
• MODULO Recruiting
  2024-515793-27-01 Phase III 1 country ANRS Maladies Infectieuses Emergentes; Centre De Recherches Et D'Etudes Sur La P…
• Phase II, multicenter, open-label, randomized, controlled, open-label clinical trial to eliminate the latent reservoir of HIV-1 by administr… Recruiting
  2024-513366-18-00 Phase II 1 country Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Caj…
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-… Recruiting
  2023-510431-11-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 ( ISLEND-… Ended
  2024-514047-28-00 Phase III 4 countries Gilead Sciences Inc.
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’… Ended
  2022-502966-26-01 Phase III 16 countries Novartis Pharma AG
• A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed dose formulations for the maintenance of virological suppression i… Ended
  2024-520388-15-00 Phase III 1 country Fondazione Penta Ets
• A single-center study to assess the effect of lamivudine (3TC) on cognitive impairment (alterations in thinking, learning, memory...) by the… Ended
  2024-514330-20-00 Phase II 1 country Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocio…
• The Italian Cohort (ITACO) and the Analytical Antiretroviral Treatment Interruption Italian Cohort (ITACO-ATI) study guided by molecular HIV… Ended
  2024-518694-33-00 Phase III 1 country Ospedale Pediatrico Bambino Gesu

Showing 1–9 of 9 trials